Brief: Reviva Announces Enrollment Update For Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
12/11/2024 13:22
Nov 12 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
RVPH.O :
* REVIVA ANNOUNCES ENROLLMENT UPDATE FOR OPEN LABEL
EXTENSION
STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA
* REVIVA PHARMACEUTICALS HOLDINGS- BRILAROXAZINE GENERALLY
WELL
TOLERATED IN PATIENTS WITH ACUTE AND STABLE SCHIZOPHRENIA
* REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FROM
1-YEAR
OLE TRIAL EXPECTED DECEMBER 2024
Source text: ID:nGNX69TTjC
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture